<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849926</url>
  </required_header>
  <id_info>
    <org_study_id>UiO_IMUTI</org_study_id>
    <nct_id>NCT01849926</nct_id>
  </id_info>
  <brief_title>Ibuprofen Versus Mecillinam for Uncomplicated Cystitis</brief_title>
  <acronym>IMUTI</acronym>
  <official_title>Ibuprofen Versus Mecillinam for Uncomplicated Cystitis in Adult, Non-pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oslo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although uncomplicated cystitis is considered to be a mild condition and mostly self&#xD;
      limiting, most patients who see a doctor will be treated with antibiotics. Antibiotics are&#xD;
      known to give a quick relief of symptoms and shorten the course of the condition by a few&#xD;
      days. The aim of this study is to evaluate ibuprofen versus mecillinam in the treatment of&#xD;
      uncomplicated cystitis in otherwise healthy, non-pregnant women. Our main objective is to see&#xD;
      whether symptomatic treatment with ibuprofen is equally efficient as treatment with&#xD;
      mecillinam in this group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design of the study will be a double blinded randomized controlled trial (RCT). Half of&#xD;
      the patients will receive treatment with mecillinam and the other half will receive treatment&#xD;
      with ibuprofen. The study will follow the principles of Good Clinical Practice (GCP).&#xD;
&#xD;
      Urine cultures will be obtained on day one and after two weeks. The patients will be given a&#xD;
      diary where they daily will register symptom load, possible complications or adverse effects&#xD;
      and on which day they feel completely cured. We will contact the patients after two weeks to&#xD;
      make sure they have followed the study procedures. After four weeks we will perform a final&#xD;
      interview with the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who are symptom free by day four</measure>
    <time_frame>Four days</time_frame>
    <description>Both symptom load with regard to specific symptoms and when feeling completely symptom free will be registered in the patient diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The patients' symptom load with regard to specific symptoms.</measure>
    <time_frame>Seven days</time_frame>
    <description>Specific symptoms, such as dysuria, urgency and pollakiuria, will be given a number from 0-6 in the patient diary, 0 = no problem and 6= as bad as it can get.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of patients who were in need of a secondary medical consult within the study period.</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients who developed an upper urinary tract infection (pyelonephritis).</measure>
    <time_frame>14 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients who experienced severe adverse effects.</measure>
    <time_frame>Seven days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients who had a relapse of symptoms within four weeks after being included in the study.</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with a positive urine culture after four weeks.</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">383</enrollment>
  <condition>Acute Cystitis (Excl in Pregnancy)</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tablet, over capsulated, 600mg three times a day for three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mecillinam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tablet, over capsulated, 200mg three times a day for three days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <arm_group_label>Ibuprofen</arm_group_label>
    <other_name>Ibux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mecillinam</intervention_name>
    <arm_group_label>Mecillinam</arm_group_label>
    <other_name>Selexid</other_name>
    <other_name>Penomax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  woman between 18 and 60 years of age&#xD;
&#xD;
          -  dysuria and pollakiuria and/or urinary urgency&#xD;
&#xD;
          -  ability to give written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy/breastfeeding child under one month of age&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  kidney disease&#xD;
&#xD;
          -  organic aciduria&#xD;
&#xD;
          -  clinical suspicion of pyelonephritis; fever, reduced general condition, upper back&#xD;
             pain&#xD;
&#xD;
          -  vaginal symptoms such as discharge or irritation&#xD;
&#xD;
          -  severe abdominal pain&#xD;
&#xD;
          -  symptoms that have lasted for more than seven days&#xD;
&#xD;
          -  one or more urinary tract infections within the lasts four weeks&#xD;
&#xD;
          -  permanent bladder catheter or use of bladder catheter within the last four weeks&#xD;
&#xD;
          -  use of antibiotics within the last two weeks&#xD;
&#xD;
          -  participated in a clinical trial within the last four weeks&#xD;
&#xD;
          -  previously undergone a pyelonephritis&#xD;
&#xD;
          -  previous allergic reaction to penicillin&#xD;
&#xD;
          -  previous allergic reaction to ibuprofen, or worsening of asthma when using&#xD;
             nonsteroidal antiinflammatory drugs(NSAIDs)&#xD;
&#xD;
          -  narrow oesophagus&#xD;
&#xD;
          -  use of the drug probenecid&#xD;
&#xD;
          -  severe gastritis or previous ulcer&#xD;
&#xD;
          -  anticoagulative treatment&#xD;
&#xD;
          -  ongoing use of steroids&#xD;
&#xD;
          -  use of immunosuppressant drugs&#xD;
&#xD;
          -  thrombocytopenia,&#xD;
&#xD;
          -  Chrohn's disease or Ulcerative colitis&#xD;
&#xD;
          -  heart insufficiency&#xD;
&#xD;
          -  severe psychiatric illness or dementia&#xD;
&#xD;
          -  severe drug addiction&#xD;
&#xD;
          -  unable to communicate in Norwegian, Swedish or Danish language&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Lindb√¶k, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo, faculty of medicine, institute for health and society, department of general medicine, antibiotic centre of primary care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oslo</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>April 4, 2013</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oslo</investigator_affiliation>
    <investigator_full_name>Morten Lindbaek</investigator_full_name>
    <investigator_title>Professor dr. med</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amdinocillin</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

